Patents by Inventor Ann Kwong
Ann Kwong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8501450Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.Type: GrantFiled: March 5, 2010Date of Patent: August 6, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
-
Publication number: 20130071834Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.Type: ApplicationFiled: June 29, 2012Publication date: March 21, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Ann Kwong, Randal Byrn, Lola M. Reid
-
Publication number: 20120295843Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.Type: ApplicationFiled: August 1, 2012Publication date: November 22, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Ann Kwong, Nagraj Mani, Yi Zhou, Chao Lin
-
Patent number: 8258116Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.Type: GrantFiled: May 5, 2008Date of Patent: September 4, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Ann Kwong, Nagraj Mani, Yi Zhou, Chao Lin
-
Patent number: 8211696Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.Type: GrantFiled: January 25, 2011Date of Patent: July 3, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Ann Kwong, Randal Byrn, Lola M. Reid
-
Publication number: 20110244549Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.Type: ApplicationFiled: March 5, 2010Publication date: October 6, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
-
Publication number: 20110229874Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.Type: ApplicationFiled: January 25, 2011Publication date: September 22, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Ann Kwong, Randal Byrn, Lola M. Reid
-
Patent number: 7879606Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.Type: GrantFiled: March 27, 2002Date of Patent: February 1, 2011Assignee: Vertex Pharmaceuticals IncorporatedInventors: Ann Kwong, Randal Byrn, Lola M Reid
-
Publication number: 20100172866Abstract: The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.Type: ApplicationFiled: May 5, 2008Publication date: July 8, 2010Applicant: Vertex Pharmaceuticals IncorporatedInventors: Ann Kwong, Nagraj Mani, Yi Zhou, Chao Lin
-
Patent number: 7705138Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.Type: GrantFiled: November 13, 2006Date of Patent: April 27, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
-
Publication number: 20070231262Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.Type: ApplicationFiled: November 13, 2006Publication date: October 4, 2007Inventors: Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
-
Publication number: 20050120398Abstract: The present invention relates to a non-transgenic, non-human animal useful as a model for protease activity and for liver damage, including steatosis.Type: ApplicationFiled: September 13, 2004Publication date: June 2, 2005Applicant: Vertex Pharmaceuticals IncorporatedInventors: Gururaj Kalkeri, Ann Kwong
-
Publication number: 20030083467Abstract: The present invention relates to novel fusion proteins, DNA molecules encoding the same, vectors comprising the DNA molecules, and host cells containing the vectors for use in measuring protease activity using a novel transcriptional assay. This invention also relates to a method for determining the inhibitory activity of a compound against a protease and to a method for comparing the activity of two proteases which recognize the same cleavage site. Kits for assaying protease activity comprising DNA molecules encoding the fusion protein substrates of this invention are also contemplated.Type: ApplicationFiled: November 20, 2002Publication date: May 1, 2003Inventors: Ursula Germann, Thomas Hoock, Ann Kwong
-
Patent number: 6528276Abstract: The present invention relates to novel fusion proteins, DNA molecules encoding the same, vectors comprising the DNA molecules, and host cells containing the vectors for use in measuring protease activity using a novel transcriptional assay. This invention also relates to a method for determining the inhibitory activity of a compound against a protease and to a method for comparing the activity of two proteases which recognize the same cleavage site. Kits for assaying protease activity comprising DNA molecules encoding the fusion protein substrates of this invention are also contemplated.Type: GrantFiled: May 12, 2000Date of Patent: March 4, 2003Assignee: Vertex Pharmaceuticals Inc.Inventors: Ursula Germann, Thomas Hoock, Ann Kwong
-
Publication number: 20020142449Abstract: The present invention provides compositions comprising cells that can effectively produce HCV after HCV infection, compositions for culturing the cells, methods for making the composition and methods for infecting the cells in the composition with HCV. The present invention also provides methods for assaying HCV production and methods for evaluating compounds that affect the production of HCV.Type: ApplicationFiled: March 27, 2002Publication date: October 3, 2002Inventors: Ann Kwong, Randal Byrn, Lola M. Reid
-
Patent number: 6117639Abstract: The present invention relates to novel fusion proteins, DNA molecules encoding the same, vectors comprising the DNA molecules, and host cells containing the vectors for use in measuring protease activity using a novel transcriptional assay. This invention also relates to a method for determining the inhibitory activity of a compound against a protease and to a method for comparing the activity of two proteases which recognize the same cleavage site. Kits for assaying protease activity comprising DNA molecules encoding the fusion protein substrates of this invention are also contemplated.Type: GrantFiled: August 31, 1998Date of Patent: September 12, 2000Assignee: Vertex Pharmaceuticals IncorporatedInventors: Ursula Germann, Thomas Hoock, Ann Kwong